Daiichi Sankyo To Launch Percutaneous Analgesic And Anti-Inflammatory Drug Loxonin(R) Gel 1% In Japan

Main Category: Pain / Anesthetics
Also Included In: Pharma Industry / Biotech Industry
Article Date: 09 Oct 2010 - 2:00 PDT


Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced the launch in Japan of its percutaneous analgesic and anti-inflammatory drug Loxonin® Gel 1% (generic name, loxoprofen sodium hydrate; approval for manufacture and marketing, June 9, 2010; drug price listing, September 24, 2010).

Loxonin® Gel 1% contains the same active ingredient, loxoprofen sodium hydrate, as found in pills and powder formulations of the leading oral analgesic and anti-inflammatory Loxonin® brand. The gel offers equivalent efficacy and can be easily applied to an affected area with no displeasing odor.

Following the launch of Loxonin® pap in 2006 and Loxonin® tape in 2008, Daiichi Sankyo is confident that this new addition to the Loxonin® lineup, which has been a long-standing top brand since 1986, will further contribute to analgesic and anti-inflammatory drug treatment in Japan.

Source: Daiichi Sankyo Company

• Additional
• References
• Citations